program book - virology educationregist2.virology-education.com/program/3rd hcvadvances.pdf ·...

PROGRAM BOOK

3rd Workshop on HCV Therapy AdvancesNew Antivirals in Clinical Practice

13 - 14 December 2013Rome, Italy

Program Book

The 3rd Workshop on HCV Therapy Advances is accredited by the European Accreditation Council for Continuing Medical Education (EACCME)

3rd Workshop on HCV Therapy Advances, Rome, Italy, 13 - 14 December 20132

Dear participant,

It is our great pleasure to welcome you to the 3rd Workshop on HCV Therapy Advances - New Antivirals in Clinical Practice.

This meeting will offer an opportunity to be educated on the latest developments in the field of Hepatitis C treatment and the promising treatment possibilities of new antivirals.

Internationally renowned speakers will present and translate the latest developments in the field of HCV therapy into daily clinical practice.

The topics are all clinically highly relevant and will be discussed in the format of clinical cases.The informal nature of the meeting will allow discussion and interaction with your fellow hepatologists, infectious disease doctors, gastro-enterologists and other health-care specialists.

The workshop has been granted 5 European CME credits by the European Accreditation Council for Continuing Medical Education (EACCME).

We thank our sponsors, Janssen Therapeutics as Gold level supporter, Abbott, Boehringer Ingelheim and Bristol-Myers Squibb as Principal Supporters, to have made this workshop possible.

We hope and trust that the workshop will be an outstanding experience and that will stimulate you in your professional life.

On behalf of the Program Committee,

WELCOME

Charles Boucher, MD, PhD

Fred Poordad, MD

Henk Reesink, MD, PhD

Stefan Zeuzem, MD


CONTENT

THE WORKSHOP IS ENDORSED BY

• Welcome p.3• Description of the workshop p.5• Target audience p.5• Learning Objectives p.5• Accreditation Statement p.5• General Information p.6• Sponsor Acknowledgements p.7• Program Committee p.8• Faculty Members p.8• Program – Friday 13 December p.10• Program – Saturday 14 December p.11• Biographies p.13


New Antivirals in Clinical Practice

DESCRIPTION

LEARNING OBJECTIVES

ACCREDITATION STATEMENT

The entrance of HCV Direct Acting Antivirals into routine clinical practices provides a great opportunity for improved care, but at the same time, substantial challenges for the treating physician.

The 3rd Workshop on HCV Therapy Advances focuses on the translation of the latest developments and treatment possibilities into daily clinical practice. The program consists of invited lectures and case discussions, presented and chaired by internationally recognized experts in the field.

TARGET AUDIENCEHepatologists, infectious disease doctors, gastro-enterologists and other healthcare professionals involved in daily care for HCV patients.

At the completion of this conference, the participant will:• Have an understanding of the basic concepts of HCV therapy• Be updated on the latest developments in the field of HCV antiviral research• Have an understanding of the challenges of HCV treatment in different patient populations• Have an overview of the advantages and possibilities of new antivirals in HCV therapy• Will know how to apply direct acting antivirals in clinical practice

Virology Education is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

The 3rd Workshop on HCV Therapy Advances – New Antivirals in Clinical Practice is designated for a maximum of 5 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

EACCME credits are recognized by the American Medical Association towards the Physician’s Recognition Award (PRA). To convert EACCME credit to AMA PRA category 1 credit, contact the AMA.

3rd Workshop on HCV Therapy Advances


GENERAL INFORMATION

BADGE POLICYAll registered delegates are provided with an identity badge. Please wear it at all times to ensure admission to the meeting.

CERTIFICATE OF ATTENDANCEA certificate of attendance can be picked up from the registration desk on Saturday 14 December.All participants need to sign the attendance list both conference days.

DATE AND VENUEThe dates of the meeting are Friday 13 December and Saturday 14 December 2013.The meeting is being held at the Crowne Plaza st Peter’s Hotel in Rome, Italy.

DISCLAIMERThis workshop is intended for educational purposes only and aims to offer participants the opportunity to share information. The Organizing Secretariat of this workshop, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this workshop. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the workshop.

EVALUATION FORMParticipants are requested to complete an evaluation form and return both forms to the registration desk upon departure. The evaluations are most helpful in planning future programs, and we appreciate your comments and suggestions. We ask you to evaluate each speaker’s presentation.

LANGUAGEThe official language of the workshop is English.

WORKSHOP SECRETARIATThe registration desk is in the foyer. The conference organizers can be addressed for questions concerning the logistics of the meeting, during all conference hours.

Biltstraat 106, 3572 BJ Utrecht, the Netherlands Phone: +31 30 230 7140, Fax: +31 30 230 [email protected] / www.virology-education.com


ACKNOWLEDGEMENTS

We wish to acknowledge the following companies that have provided an educational grant in support of this event:

GOLD LEVEL SUPPORTER

ACADEMIC SUPPORTERS

PRINCIPAL SUPPORTERS

A Promise for Life


PROGRAM COMMITTEE

Charles Boucher, MD, PhD

Professor in the Department of Virology of the Erasmus University Medical CenterRotterdam, The Netherlands

Fred Poordad, MD

Professor of Medicine at the University of San Antonio Health Science CenterSan Antonio, Texas, USA

Henk Reesink, MD, PhD

Associate Professor in the Department of Gastroenterology and Hepatology of the Academic Medical Center at the University of Amsterdam, The Netherlands.

Stefan Zeuzem, MD

Professor of Medicine and Chief of the Department of Medicine I, at the J.W. Goethe University Hospital, Frankfurt, Germany

Maria Buti, MD, PhD

Professor of Medicine and Chief of Internal Medicine and HepatologyHospital General Universitari Valle HebronBarcelona, Spain

Marc Bourlière, MD

Head of Hepato-Gastroenterology department Hôspital Saint JosephMarseille, France.

FACULTY MEMBERS


Carlo Federico Perno, MD, PhD

Professor of Virology University of Rome “Tor Vergata”Rome, Italy

Stefano Vella, MD

Director of the Department of Pharmacological Research and Medicines EvaluationChair, HIV, Hepatitis & Global Health Group at the Istituto Superiore di Sanità (ISS)Rome, Italy

FACULTY MEMBERS

Massimo Colombo, MD

Professor of GastroenterologyUniversity of MilanMilan, Italy

Geoffrey Dusheiko, MD, MB, BCh

Professor of Medicine at the Royal Free Hospital and Univ. College School of Medicine,London, United Kingdom

Rafael Esteban, MD

Head of Internal Medicine and Liver Unit of the Hospital Universitario Valle Hebron, Barcelona and Professor of Medicine at the Universidad Autonoma de BarcelonaBarcelona, Spain

Peter Ferenci, MD

Professor of Medicine at the department of Internal Medicine III, Vienna General Hospital Medical University of ViennaVienna, Austria

Christoph Sarrazin, MD

Professor of Medicine at J.W. Goethe-University HospitalFrankfurt, Germany

Heiner Wedemeyer, MD

Research Group Leader in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical SchoolHannover, Germany


PROGRAMFriday 13 December

11:00h Satellite Symposium Janssen Therapeutics EMEA

Triple Therapy in the Near Future: New Opportunities to Cure

12.30h Lunch

13.30h Opening of the Workshop

Session 1 DAA’s in combination with pegylated interferon and ribavineChairs Stefano Vella & Massimo Colombo

13:45h Boceprevir and telaprevir: efficacy and side effects, what have we learned in 2013

Fred Poordad, MD University of San Antonio Health Science Center, USA

14:15h Novel DAA’s combined with PEG/RIBA

Heiner Wedemeyer, MD Hannover Medical School, Germany

14:45h Discussion

Session 2 DAA’s in clinical development: what are the key 2013 findingsChairs Stefan Zeuzem & Rafael Esteban

15:00h Industry presentation: Janssen TherapeuticsMaria Beumont, MD

Janssen Infectious Diseases – Diagnostics BVBA, Belgium15:30h Panel Discussion: Key Findings 2013

16:00h Coffee Break

Session 3 Challenging Patient PopulationsChairs Maria Buti & Henk Reesink

16:30h Management and monitoring of HCCi in the future era of DAA’s

Massimo Colombo, MD University of Milan, Italy

17:00h The current challenges in treating cirrhotic patients

Mark Bourlière, MD Hôspital Saint Joseph, Marseille, France

17:30h Discussion

18:00h Adjournment for the day

20:00h Workshop Dinner


Saturday 14 DecemberPROGRAM

Session 4 Genotype 2 & 3 and drug resistanceChairs Fred Poordad & Peter Ferenci08:30h Treating HCV genotype 2 & 3

Christophe Sarrazin, MD J.W. Goethe University Hospital, Germany

09:00h Drug resistance findings observed in clinical practice: implications for patient management

Carlo Federico Perno, MD, PhD University of Rome “Tor Vergata”, Italy

09:30h Latest insights from NUC-containing regimens: what is the best partner molecule?

Geoffrey Dusheiko, MD UCL Institute for Liver and Health, Royal Free Hospital, United Kingdom

10:00h Discussion

10:15h Coffee Break

Session 5 Interferon free regimesChairs: Christophe Sarrazin & Carlo Federico Perno

10:45h NUC sparing regimens: where do we stand

Stefan Zeuzem, MD J.W. Goethe University Hospital, Germany

11:15h Update: Early investigational trials

Peter Ferenci, MD Medical University of Vienna, Austria

11:45h Discussion

12:00h Closure & Lunch


3rd Workshop on HCV THERAPY ADVANCES

New Antivirals in Clinical Practice

Biographies

Marc Bourlière, MDHôspital Saint Joseph, Marseille, France

Marc Bourlière, MD, received his medical degree in 1987 from Marseilles University in Marseile, France. He completed his fellowship training at Marseilles University hospital and in Beaujon University hospital in Paris. He was assistant in Hepatology in Conception University hospital in Marseilles before taking up his current position as head of the Hepato-Gastroenterology department at Hospital Saint Joseph also in Marseilles.

Dr Bourlière and his group have participated in hepatitis B and C and HCC clinical trials; His current research focus is the use and development of non invasive biomarkers in hepatitis and the development of new antiviral therapy for hepatitis C.

Dr Bourlière has published more than 150 papers or chapters in international journals and books focused on hepatitis B and C. As well as reviewing for many specialist journals, he has served as member of the editorial board of Gastroenterologie , Clinique et Biologique. Dr Bourlière belongs to the French Agency for AIDS and hepatitis research (ANRS) and he heads the ANRS group that coordinates hepatitis clinical therapeutic trials (AC24). He is also member of several professional societies including the French and European associations for the study of the liver.

Disclosure No financial relationships

Charles Boucher, MD, PhDErasmus Medical Center, The Netherlands

Charles Boucher, MD, PhD, is Professor in the Department of Virology Erasmus Medical Center, Erasmus University Rotterdam, the Netherlands. Dr Boucher received his medical degree cum laude from the Faculty of Medicine of the University of Amsterdam, The Netherlands.

Specializing in medical microbiology, he also received a PhD degree from that institution.

He then continued his studies in clinical microbiology and virology at the Academic Medical Center, Amsterdam and the University Medical Center Utrecht. He is the chairman of the European Society for Antiviral Resistance. He authored over 240 publications.

Dr Boucher is an organizer of international workshops, meetings and conferences, a consultant throughout Europe and the United States, a reviewer for scientific journals and cochairman of several international committees. He is the author of numerous publications that have appeared in such journals as Science, The Lancet, Nature Medicine, Journal of Infectious Diseases and AIDS.

Disclosure Financial relationships with Abbott, Merck, Roche, ViiV Healthcare


Massimo Colombo, MDUniversity of Milan, Milan, Italy

Massimo Colombo, MD is Professor of Gastroenterology at the University of Milan, Italy. His research studies interests include diagnosis and treatment of viral hepatitis and liver cancer. He is Chairman of Department of Liver, Kidney, Lung and Bone Marrow Units and Organ Transplant and of the 1st Division of Gastroenterology and at the Policlinic University Hospital, Milan.

Prof. Colombo received a medical degree in Medicine at University of Milan where he completed a residency in Gastroenterology at Policlinic Maggiore Hospital. He completed fellowship in Liver Disease at the Mount Sinai Hospital in New York.

Prof. Colombo has been the Editor-in-Chief of the Journal of Hepatology. He is affiliated with several professional Associations and Societies, including the American Association for the Study of the Liver and the European Association for the Study of the Liver and other professional bodies in Italy. He is an international lecturer and speaker, sits in the editorial board of many Hepatology journals globally and has published more than 300 original manuscripts in peer-reviewed journals; H-index = 39. In 2010 he received the EASL Recognition Award by the European Association for the Study of the Liver (2010) for outstanding medical and scientific contribution.


Maria Buti, MD, PhDHospital General Universitari Valle Hebron, Barcelona, Spain

Maria Buti, MD. PhD earned her medical degree at the University of Barcelona and her PhD in Internal Medicine at the University “Autónoma” de Barcelona, Spain. She is currently Professor of Medicine and Chief of Internal Medicine and Hepatology at the Hospital General Universitari Valle Hebron, Barcelona. Dr Butí has worked in viral hepatitis for the last 15 years, particularly in diagnosis and therapy of hepatitis B and C. She has been published widely in the field of liver disease, with numerous papers and contributions to books.

Dr Butí was the Secretary of the Spanish Association for the Study of Liver Diseases, and an active member of the EASL, and the AASLD and various professional societies.



Geoffrey Dusheiko, MD, MB, BChRoyal Free Hospital, London, United Kingdom

Geoffrey Dusheiko, MD, MB, BCh, is a professor of Medicine at the Royal Free Hospital and University College School of Medicine, London, UK. He earned his bachelor of medicine, bachelor of surgery degree from the University of Witwatersrand in Johannesburg, South Africa. After graduating, he completed his internship at Baragwanath Hospital in Johannesburg and his residency at Johannesburg Hospital. His fellowships were conducted at the Johannesburg Hospital Liver Unit and the National Institutes of Health in Maryland and the University of Minnesota, United States. Dr. Dusheiko’s research interests include the management and treatment of hepatitis B and C and small hepatocellular carcinoma; he has a special interest in research in viral hepatitis, focused on viral genotyping, applied molecular virology, the natural history of chronic viral hepatitis, and antiviral therapies. He has served on editorial boards for the Journal of Viral Hepatitis, Hepatology, and Best Practice and Research: Clinical Gastroenterology, GUT among others, and is the author of more than 300 published articles. A member of several organizations, including IASL, AASLD, and EASL, he is a fellow of the Royal College of Physicians, the Royal College of Physicians of South Africa, and the Royal College of Physicians of Edinburgh. He served as Educational Councilor on the Governing Board of the European Association for the Study of the Liver for 4 years.

Disclosure Financial relationships with Vertex, Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Glaxo Smith Kline, Human Genome Sciences, Pharmasset, Novartis, Pfizer, Roche/Genentech, Schering Plough/Merck, Tibotec, Achillion, Janssen, Zymogenetics

Rafael Esteban, MDHospital General Universitari Valle Hebron, Barcelona, Spain

Rafael Esteban, MD is Head of the Internal Medicine and Liver Unit of the Hospital Universitari Valle Hebron, Barcelona, Spain and Professor of Medicine at the Universidad Autonoma de Barcelona.

Dr. Esteban is a member of the American Association for the Study of Liver Diseases (AASLD). He had been member of the Scientific Committee of the European Association for the Study of the Liver (EASL) and Secretary of the Spanish Association for the Study of Liver Diseases (AEEH). Dr. Esteban is president of Spanish association for the study of the liver and on the Editorial Board of Journal Hepatology and editor of Hepatology Reviews.

Dr. Esteban has authored more than 350 original articles in peer-reviewed journals on the subject of viral hepatitis

Disclosure Financial relationships with BMS, MSD, Glaxo, Novartis, Janssen, Abbvie and Gilead


Peter Ferenci, MDMedical University of Vienna, Vienna, Austria

Peter Ferenci, MD was born in Hungary and graduated from the Medical University of Vienna, Austria in 1972. He trained in internal medicine and Gastroenterology/Hepatology in Vienna and at the Liver Unit, National Institutes of Health (Bethesda, MD, USA). His special interests focus on chronic viral hepatitis, genetic liver diseases and hepatic encephalopathy. Since 1990, Dr. Ferenci has been Professor of Medicine at the Medical University of Vienna, Austria. In 2004, he was promoted Dr. honoris causae at the University of Cluj Napoca, Romania and in 2011 at the Semmelweis University, Budapest. In 2008, he received the prestigious EASL recognition award.

Dr. Ferenci is a member of the European Association for the Study the Liver (EASL), the American Association for the Study of Liver Diseases (AASLD) and fellow of the American Gastroenterological Association (AGA). He was President of the Austrian Association of Gastroenterology and Hepatology, 1996–1998, and in 2005 chairman of the United European Gastroenterology Federation (UEGF). He was the program director of the 11th World Congresses of Gastroenterology, Vienna 1998 and the organizer of the 27th Annual Meeting of EASL 1992.

Dr. Ferenci has published over 600 papers and abstracts including authoritative papers on various topics in liver diseases and is the author or editor of one book and of 20 chapters in leading textbooks. His research focuses on treatment of chronic viral hepatitis, inherited liver diseases and on liver failure.

Disclosure Financial relationships with Roche, Rottapharm-Madaus, Boehringer Ingelheim, Janssen, Gilead, BMS, Merck, GSK, Idenix, and Achilleon.

Carlo Federico Perno, MD, PhDUniversity of Rome, Rome, Italy

Carlo-Federico Perno, MD is a Professor of Virology at the University of Rome ‘Tor Vergata’, Italy, and Director of the Unit of Molecular Virology at the Tor Vergata University Hospital, Rome, Italy. He also works as consultant of Clinical Virology at the Spallanzani Hospital for Infectious Diseases.

Professor Perno gained his MD from the University of Rome in 1980, and graduated in oncology in 1983. From 1986 to 1989 he worked as Research Fellow at the National Cancer Institute, Bethesda, Maryland, USA, where he collaborated to the discovery and clinical application of the first antiviral drugs used in the therapy of HIV infection, including AZT, ddC, d4T and ddI.

Professor Perno has written hundreds of scientific publications, including peer reviewed articles in high ranking journals (Nature, Science, Lancet, PNAS, J Experimental Medicine, PNAS), mostly dedicated to HIV therapy. In 2001 the European Community awarded him the Descartes Award for excellence in the antiviral field. He has a major expertise in antiviral therapy, clinical interpretation and therapeutic application of antiviral resistance testing



Fred Poordad, MDTexas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA

Fred Poordad, MD, is professor of medicine at the University of Texas Health Science Center, San Antonio, and VP, Academic and Clinical Affairs at The Texas Liver Institute in San Antonio. Dr. Poordad received his bachelor and medical doctorate at the University of Alberta in Edmonton. He completed a residency in internal medicine at St. Thomas Medical Center and Northeastern Ohio Universities College of Medicine. Dr. Poordad also completed fellowships in gastroenterology at the University of South Carolina and in hepatology/liver transplantation at the Johns Hopkins University School of Medicine.

Dr. Poordad served as the co-director of liver transplantation at Johns Hopkins prior to becoming the chief of hepatology and liver transplantation at Cedars-Sinai Medical Center in Los Angeles for 10 years. In 2012, he joined The Texas Liver Institute as vice president of academic and clinical affairs and faculty at the University of Texas Health Science Center in San Antonio. He teaches medical students, resident and fellows, rotates on the liver transplant service, and conducts a multitude of clinical research across all facets of liver disease, including viral hepatitis, fatty liver and cirrhosis.

A member of the American Medical Association, the American Association for the Study of Liver Diseases, the European Society for the Study of Liver, the American Society of Transplantation and the International Liver Transplantation Society, Dr. Poordad lectures both nationally and internationally on the topic of liver disease and transplantation. Dr. Poordad has over 300 publications including numerous book chapters, abstracts, educational monographs and publishes in such journals as Gastroenterology, Hepatology, Liver Transplantation, the New England Journal of Medicine, Journal of Hepatology, the American Journal of Transplantation, and the International Journal of Artificial Organs.

Dr. Poordad serves or has served on educational committees for the American Association for the Study of Liver Disease, the American Society of Transplantation, and the American College of Gastroenterology. He is on the editorial board of several journals, and is a regular peer reviewer for multiple journals, as well as for the AGA and AASLD annual meetings.

Disclosure Financial relationships: Abbott Laboratories, Achillion Pharmaceuticals, Anadys Pharmaceuticals, Biolex Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, GlobeImmune, Idenix Pharmaceuticals, Idera Pharmaceuticals, Inhibitex Pharmaceuticals, Intercept Pharmaceuticals, Janssen, Kadmon, Medarex, Medtronic, Merck & Co., Novartis, Onyx/Bayer, Pharmasset, Roche/Genentech, Schering-Plough, Santaris Pharmaceuticals, Salix, Scynexis Pharmaceuticals, Theravance, Vertex Pharmaceuticals, ViroChem Pharma, ZymoGenetics;


Christoph Sarrazin, MDJW Goethe University Hospital, Frankfurt, Germany

Christoph Sarrazin, MD is Professor of Medicine at J.W. Goethe-University Hospital Frankfurt, Germany. He trained at the Medical Schools in Bonn and Würzburg and graduated in Medicine in 1994. He served as a postdoctoral fellow with specialisation in Internal Medicine, Gastroenterology and Hepatology at J.W. Goethe-University Hospital from 1994 to 2002 including a Research Scholarships at the Scientific Research Institute “Georg-Speyer-Haus”, Frankfurt.

In July 2002, Christoph Sarrazin moved as Assistant Professor of Medicine to Saarland University Hospital, Homburg, Germany and in 2007 he became an Associate Professor. Also in 2007 he moved back to J.W. Goethe-University Hospital in Frankfurt as Associate Director of the Department of Internal Medicine 1. Dr. Sarrazin took over his current position as Professor of Medicine at J.W. Goethe-University Hospital in Frankfurt in 2009. For more than 10 years, Christoph Sarrazin has worked on basic and clinical aspects of hepatitis virus infections. He participated in numerous national and international phase I-III studies in chronic viral hepatitis.

Dr. Sarrazin has more than 200 publications on basic research and clinical aspects of chronic liver diseases as well as evaluation of HCV and HBV molecular assays. His main interests in basis research are viral determinants of resistance to treatment of viral hepatitis with interferon, ribavirin and direct antiviral drugs

Disclosure Financial relationships with Abbott, Abbvie, Boehringer Ingelheim, Bristol-Myers Squibb, Janssen, Merck/MSD, Novartis, Gilead Sciences, Roche, Siemens, Vertex.

Henk Reesink, MD, PhDAcademic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

Hendrik W. Reesink, MD, PhD, is Associate Professor in the Dept. of Gastroenterology and Hepatology of the Academic Medical Center, University of Amsterdam, The Netherlands.After receiving his medical degree from the Faculty of Medicine of the University of Amsterdam The Netherlands, he specialised in immuno-hematology and transfusion medicine at the Central Laboratory of The Netherlands Blood Transfusion Service, linked to the University of Amsterdam and subsequently he got his training in internal medicine at the Wilhelmina Gasthuis, of the University of Amsterdam. He also received a PhD degree from that institution.He was the director of the Blood Bank in Amsterdam for almost 30 years and worked as general internist at the Onze Lieve Vrouwe Gasthuis for more than 25 years. He works since 2004 exclusively in the Academic Medical Center as internist/ hepatologist with special focus on viral hepatitis research.Dr Reesink interest in research was in the past focussed on blood borne infectious diseases and the prevention of transfusion transmitted infectious agents, next to the improvement of the quality and safety of blood components for clinical practise. Over the last 10 years his research interest is mainly in the early development and evaluation of new medicines for the treatment and cure of chronic hepatitis B and C patients.

Disclosure Financial relationships with Gilead, Merck, Roche, Vertex, GlaxoSmithKline, Janssen-Cilag, PRA International, Boehringer Ingelheim, Anadys, Santaris, Astex, Idenix, Bristol-Myers Squibb, SGS, Regulus, Santaris, R-Pharm.


Stefano Vella, MDIstituto Superiore di Sanità, Rome, Italy

Stefano Vella (Rome, June 12, 1952) received his degree in Medicine from the University of Rome in 1977. He subsequently achieved specialty degrees in both Infectious Diseases (1982) and Internal Medicine (1987).

After a postdoctoral experience at the University of Pennsylvania (1981-1982), he joined the medical staff at the Institute of Internal Medicine, University La Sapienza, Rome, where he developed an extensive experience in the clinical management of patients with infectious diseases and with HIV/AIDS, and started his research career, mainly devoted to the study of the pathogenesis and the therapy of viral infections.

In 1991, Dr Vella was appointed Research Director of HIV/AIDS at the Istituto Superiore di Sanità (ISS), the Italian National Institute of Health. Since 2003, he is the Head of the Department of Therapeutic Research and Medicines Evaluation of the ISS. Over the last twenty years, his research group published extensively on various aspects of HIV pathogenesis, treatment and prevention.

His research interest is mainly directed towards: the study of HIV resistance to antiretroviral drugs; the mechanisms of immune reconstitution; the perfecting of antiretroviral therapy.

He is actively involved in HIV-HCV confection and coordinates the NEAT study, the european commission funded project on HIV/AIDS clinical research, which involved 40 partners from 16 european countries.



Heiner Wedemeyer, MDHanover Medical School, Hanover, Germany

Heiner Wedemeyer, MD, is managing senior physician and associate professor in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School (Director Prof. Dr. M.P. Manns). He coordinates the hepatitis diagnostic laboratory of Hannover Medical School and, together with PD Dr. Markus Cornberg, he is leading a research group on cellular immunology in viral hepatitis.

Heiner Wedemeyer studied Musicology and Medicine and graduated in Medicine at the University of Göttingen in 1996. He started training in Internal Medicine at Hannover Medical School, Germany. From 1998-2000 he spent 2 1/2 years as a research fellow in immunology in the Liver Diseases Section at the National Institutes of Health in Bethesda, Maryland, in the group of Barbara Rehermann. In 2001 he returned to Hannover and completed his specialist training in Gastroenterology and Hepatology. Heiner Wedemeyer is Fellow of the European Board of Gastroenterology and Hepatology.

Since 2002 Heiner Wedemeyer is involved in the scientific coordination of the German Network of Competence on Viral Hepatitis (Hep-Net) and the German Liver Foundation (since 2006). In 2008 he was elected as member of the Scientific Comittee of the European Association for the Study of the Liver (EASL) and was leading EASL as the Secretary General from 2009-2011. Heiner Wedemeyer had various coordinating responsibilities in the establishment of several national and international guidelines on the management of hepatitis B and C and hepatocellular carcinoma. Heiner Wedemeyer has worked on basic and clinical aspects of hepatitis virus infections since 1996. His main interest is the immunopathogenesis of HBV, HCV, HDV and HEV infection and the development of novel immunomodulatory therapies such as therapeutic vaccines in hepatitis C. Heiner Wedemeyer has been principal investigator in several phase I-IV clinical trials on antivirals and immunotherapies in viral hepatitis.

Prof. Wedemeyer has published more that 160 original articles, 90 reviews and editorials and 50 book chapters. He is editor of 4 books. The current Hirsch-Index of Heiner Wedemeyer is 46 und his publications have been cited more than 10.000 times. He has been awarded with the Hans Popper Award of the International Association for the Study of the Liver (2002), the “Präventionspreis der Deutschen Gesellschaft für Innere Medizin” (2008), the Innovation Award of the German Medical Faculties (2011) and the Rudolph-Schoen-Award (2011). The research of Heiner Wedemeyer has been funded by the Deutsche Forschungsgemeinschaft, the German Ministry for Research and Education (BMBF), the European Union, the European Association for the study of the Liver, the Network of Competence on Viral Hepatitis (Hep-Net), the Robert-Koch-Institute and the Bill and Melinda Gates foundation.

Disclosure Financial relationship with Abbott, Abbvie, Biolex, Bristol-Myers Squibb, Boehringer Ingelheim, Gilead, ITS, Janssen/Cilag, Medgenics, Merck, Novartis, Roche, Roche Diagnostics, Siemens, Transgene, ViiV Healthcare.


Stefan Zeuzem, MDJ.W. Goethe University Hospital, Frankfurt am Main, Germany

Stefan Zeuzem MD, holds the positions of Professor of Medicine and Chief of the Department of Medicine I, at the J.W. Goethe University Hospital, Frankfurt, Germany. His clinical areas of expertise include gastroenterology, hepatology, liver transplantation, endoscopy, gastrointestinal oncology and endocrinology. Professor Zeuzem is a member of numerous professional associations and has co-authored manuscripts, book chapters, and reviews encompassing varied aspects of internal medicine. In addition, he has been recognized with many honors and awards for his outstanding research accomplishments.

His current research interests include cellular physiology, molecular biology of hepatitis viruses, viral kinetics, the role of hepatitis C in hepatocarcinogenesis, and the stratification and optimization of antiviral treatment.

After receiving his medical training from J. W. Goethe University Medical School, Frankfurt am Main, Germany; the School of Clinical Medicine, University of Cambridge, United Kingdom; and the Medical School, University of Newcastle upon Tyne, also in the United Kingdom, Professor Zeuzem completed post-doctoral fellowships in Endocrinology and Gastroenterology at the University Hospital, Frankfurt am Main, Germany. Subsequently, he completed research sabbaticals with the Department of Medicine and Clinical Biochemistry, Royal Victorian Infirmary, Newcastle upon Tyne, UK; at the Max-Planck-Institute for Biophysics, Frankfurt am Main, Germany; and at the Howard Hughes Medical Institute, Boyer Center of Molecular Medicine, Yale University Medical School, New Haven, Connecticut, USA. From 2002 to 2006 he was a full Professor of Medicine and Chairman of the Department of Internal Medicine II at Saarland University Hospital, Homburg/Saar, Germany

Disclosure Financial relationship with Abbvie, BMS, Boehringer Ingelheim, Gilead, Idenix, Janssen, Merck, Novartis, Roche, Santaris, Vertex


HEPATITIS - RELATED WORKSHOPS - 2014organized by Virology Education

12th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance26 - 28 March 2014 - Barcelona, Spain

WWW.VIROLOGY-EDUCATION.COM

3rd Asian Conference on Hepatitis & AIDS - From Basic Science to Clinical Practice9 - 10 May 2014 - Beijing, China

ACHA

10th International Workshop on HIV & Hepatitis Co-infection12 - 14 June 2014 - Paris, France

15th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy19 - 21 May 2014 - Washington DC, USA

HIVHepatitis

2nd International Workshop on the Use of DAAs in Advanced Liver Disease and Transplantation8 April 2014 - London, United Kingdom

9th International Workshop on Hepatitis C - Resistance & New Compounds13 April 2014 - London, United Kingdom

1st International Hepatitis Cure & Eradication Meeting6 - 7 November 2014 - Toronto, Canada

3rd Latin American Meeting on Treatment of Viral Hepatitis6 - 7 June 2014 - São Paulo, Brazil

TREATMENTOF VIRAL HEPATITIS

Thomas W, 42, Physician

for a Hep C-free world

© 2013 Janssen Pharmaceutica N.V. – CoE/TMC435/0813/0046

Aiming for a world without Hepatitis C

and neither can we At Janssen Therapeutics EMEA, we can’t wait to eradicate Hepatitis C. It’s what our new organisation within Janssen is all about.

100% focus on defeating HCV. Nothing else.

786204245_001_A4_JournalAd_ENGLISH_NO_web_address.indd 1 18/11/2013 11:23

12 - 13 December 2014

WWW.VIROLOGY-EDUCATION.COM

SAVE THE DATE

program book - virology educationregist2.virology-education.com/program/3rd hcvadvances.pdf ·...

Documents